GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuno-Biological Laboratories Co Ltd (TSE:4570) » Definitions » Cyclically Adjusted Revenue per Share

Immuno-Biological Laboratories Co (TSE:4570) Cyclically Adjusted Revenue per Share : 円0.00 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Immuno-Biological Laboratories Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Immuno-Biological Laboratories Co's adjusted revenue per share for the three months ended in Sep. 2024 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Immuno-Biological Laboratories Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Immuno-Biological Laboratories Co was -3.50% per year. The lowest was -8.70% per year. And the median was -7.45% per year.

As of today (2025-05-28), Immuno-Biological Laboratories Co's current stock price is 円528.00. Immuno-Biological Laboratories Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was 円0.00. Immuno-Biological Laboratories Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Immuno-Biological Laboratories Co was 9.83. The lowest was 2.92. And the median was 5.07.


Immuno-Biological Laboratories Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Immuno-Biological Laboratories Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuno-Biological Laboratories Co Cyclically Adjusted Revenue per Share Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.28 105.15 97.57 94.98 94.63

Immuno-Biological Laboratories Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.67 96.16 95.40 94.63 -

Competitive Comparison of Immuno-Biological Laboratories Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuno-Biological Laboratories Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's Cyclically Adjusted PS Ratio falls into.


;
;

Immuno-Biological Laboratories Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Immuno-Biological Laboratories Co's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0/108.9000*108.9000
=0.000

Current CPI (Sep. 2024) = 108.9000.

Immuno-Biological Laboratories Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 25.383 98.500 28.063
201412 22.439 97.900 24.960
201503 45.375 97.900 50.473
201506 19.084 98.400 21.120
201509 22.316 98.500 24.672
201512 32.584 98.100 36.171
201603 34.556 97.900 38.439
201606 19.627 98.100 21.788
201609 28.710 98.000 31.903
201612 21.980 98.400 24.325
201703 31.034 98.100 34.451
201706 17.898 98.500 19.788
201709 27.042 98.800 29.806
201712 23.117 99.400 25.326
201803 30.418 99.200 33.392
201806 20.431 99.200 22.429
201809 25.264 99.900 27.540
201812 23.079 99.700 25.209
201903 23.207 99.700 25.348
201906 12.991 99.800 14.176
201909 13.476 100.100 14.661
201912 18.225 100.500 19.748
202003 20.062 100.300 21.782
202006 12.520 99.900 13.648
202009 14.105 99.900 15.376
202012 17.891 99.300 19.621
202103 20.205 99.900 22.025
202106 13.438 99.500 14.708
202109 13.835 100.100 15.051
202112 20.825 100.100 22.656
202203 21.421 101.100 23.074
202206 16.800 101.800 17.972
202209 14.679 103.100 15.505
202212 28.105 104.100 29.401
202303 25.740 104.400 26.849
202306 19.026 105.200 19.695
202309 20.222 106.200 20.736
202312 19.638 106.800 20.024
202403 28.809 107.200 29.266
202409 0.000 108.900 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Immuno-Biological Laboratories Co  (TSE:4570) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Immuno-Biological Laboratories Co was 9.83. The lowest was 2.92. And the median was 5.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Immuno-Biological Laboratories Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Immuno-Biological Laboratories Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuno-Biological Laboratories Co Business Description

Traded in Other Exchanges
N/A
Address
1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.

Immuno-Biological Laboratories Co Headlines

No Headlines